Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes

被引:87
作者
Herrlin, K [1 ]
Yasui-Furukori, N
Tybring, G
Widén, J
Gustafsson, LL
Bertilsson, L
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden
关键词
adverse effect; antidepressant; citalopram; CYP2C19; CYP2D6; enantiomers; genotype; mania; mephenytoin; metabolism; metabolic ratio; metabolites; pharmacokinetics; phenotype; stereoisomerism; Swedes; yawning;
D O I
10.1046/j.1365-2125.2003.01874.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To investigate pharmacokinetics of the enantiomers of citalopram (CT) and its metabolites desmethylcitalopram (DCT) and didesmethylcitalopram (DDCT) in Swedish healthy volunteers in relation to CYP2C19 and CYP2D6 geno- and phenotypes. Methods Racemic CT was given for seven days to panels with different genotypes and the following mephenytoin (Me) and debrisoquine (De) hydroxylation phenotypes: EMDe / EMMe, PMDe / EMMe, EMDe / PMMe ( n = 6 in all groups), and one PMDe/ PMMe subject. Blood sampling was carried out during day 7, and all urine was collected for 12 h after the last dose of CT. Results The AUC of S-CT was significantly higher in the EMDe / PMMe panel compared to the EMDe / EMMe and PMDe / EMMe panels ( P < 0.05), whereas the AUC of R-CT did not differ between the panels. Similar differences, although they did not reach statistical significance, were noted for S-DCT and R-DCT. The enantiomers of DDCT were not quantifiable in PMDe, and there was no difference in DDCT enantiomer concentrations between the other two panels. A PMDe / PMMe subject stopped taking CT after five days due to severe adverse effects. Based on two time points, this subject had a very long CT half-life of 95 h. The value of 1.0 for the S/R ratio of the CT trough in this subject was similar to the mean S/R CT trough ratio of the EMDe / PMMe panel, but higher than the S/R CT ratio of the EMDe / EMMe panel (0.56; 95% CI 0.49 - 0.63) and the PMDe / EMMe panel (0.44; 95% CI 0.31 - 0.57). Thus the latter two phenotypes eliminated S-CT more rapidly via CYP2C19. An adverse effect described as an 'alcohol hangover' feeling was reported by one subject from each of the three panels. These individuals had the highest concentrations of both CT enantiomers. Conclusions The AUC of S-, but not R-(CT) was found to be significantly higher in PM of mephenytoin compared to EMs, PMs may need a lower dosage of CT.
引用
收藏
页码:415 / 421
页数:7
相关论文
共 28 条
  • [1] The neuropharmacology of yawning
    Argiolas, A
    Melis, MR
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 343 (01) : 1 - 16
  • [2] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [3] BRYOIS C, 1994, ARCH GEN PSYCHIAT, V51, P664
  • [4] THE EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS ON CYTOCHROME-P4502D6 (CYP2D6) ACTIVITY IN HUMAN LIVER-MICROSOMES
    CREWE, HK
    LENNARD, MS
    TUCKER, GT
    WOODS, FR
    HADDOCK, RE
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 34 (03) : 262 - 265
  • [5] Foglia JP, 1997, PSYCHOPHARMACOL BULL, V33, P109
  • [6] Fredricson OK, 1982, PROG NEUROPSYCHOPHAR, V6, P311
  • [7] CITALOPRAM - INTERACTION STUDIES WITH LEVOMEPROMAZINE, IMIPRAMINE, AND LITHIUM
    GRAM, LF
    HANSEN, MGJ
    SINDRUP, SH
    BROSEN, K
    POULSEN, JH
    AAESJORGENSEN, T
    OVERO, KF
    [J]. THERAPEUTIC DRUG MONITORING, 1993, 15 (01) : 18 - 24
  • [8] Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
    Herrlin, K
    Massele, AY
    Jande, M
    Alm, C
    Tybring, G
    Abdi, YA
    Wennerholm, A
    Johansson, I
    Dahl, ML
    Bertilsson, L
    Gustafsson, LL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) : 391 - 401
  • [9] SEROTONIN, PANIC DISORDER AND AGORAPHOBIA - SHORT-TERM AND LONG-TERM EFFICACY OF CITALOPRAM IN PANIC DISORDERS
    HUMBLE, M
    WISTEDT, B
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 6 : 21 - 39
  • [10] NEUROCHEMICAL CHARACTERIZATION OF A NEW POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITOR - LU-10-171
    HYTTEL, J
    [J]. PSYCHOPHARMACOLOGY, 1977, 51 (03) : 225 - 233